<p>A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers</p>

Abstract

The data from this study can be used to guide rational drug dosing and choose therapeutic regimens in subsequent clinical studies.